Bohuslav Melichar
Palacký University Olomouc(CZ)
Publications by Year
Research Areas
Renal cell carcinoma treatment, Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics, Pancreatic and Hepatic Oncology Research, Renal and related cancers
Most-Cited Works
- → Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma(2018)4,537 cited
- → Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma(2019)3,317 cited
- → Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study(2019)3,089 cited
- → Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial(2007)2,219 cited
- → Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial(2013)2,179 cited
- → Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial